Leukemia, Acute Myeloid malady

Genetic diseases, Rare diseases, Blood diseases, Cancer diseases, Immune diseases categories

Aliases & Classifications for Leukemia, Acute Myeloid

About this section

Aliases & Descriptions for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 46 30
Acute Myeloid Leukemia 30 8 10 32
Aml - Acute Myeloid Leukemia 8 22
Leukemia, Acute Myelogenous 46 9
Leukemia, Myelocytic, Acute 8 61
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 46
Leukemia, Acute Myeloid, Reduced Survival in 46
Leukemia, Acute Myeloid, Somatic 46
Leukemia, Acute Myeloblastic 9
Myelogenous Leukemia, Acute 9
Acute Myeloblastic Leukemia 8
Acute Myelocytic Leukemia 42


External Ids:

OMIM46 601626
Disease Ontology8 DOID:9119
ICD9CM27 205.0
MeSH33 D015470

Summaries for Leukemia, Acute Myeloid

About this section
MedlinePlus:32 Leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, however, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. in acute myeloid leukemia (aml), there are too many of a specific type of white blood cell called a myeloblast. aml is the most common type of acute leukemia in adults. this type of cancer usually gets worse quickly if it is not treated. possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. symptoms of aml include: fever shortness of breath easy bruising or bleeding bleeding under the skin weakness or feeling tired weight loss or loss of appetite tests that examine the blood and bone marrow diagnose aml. treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. once the leukemia is in remission, you need additional treatment to make sure that it does not come back. nih: national cancer institute

MalaCards based summary: Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to myelodysplastic syndrome and myelofibrosis, and has symptoms including autosomal dominant inheritanceand acute myeloid leukemia. An important gene associated with Leukemia, Acute Myeloid is PICALM (phosphatidylinositol binding clathrin assembly protein), and among its related pathways are Dorso-ventral axis formation and IL-3 Signaling Pathway. The drugs cyclophosphamide and etoposide and the compounds beta-tyrosine and tandutinib have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are liver/biliary system and reproductive system.

Disease Ontology:8 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

Description from OMIM:46 601626

Related Diseases for Leukemia, Acute Myeloid

About this section

Diseases in the Myeloid Leukemia family:

leukemia, acute myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia, Adult
Npm1-Related Acute Myeloid Leukemia Inherited Acute Myeloid Leukemia
'acute Myeloid Leukemia with T(9;11)(p22;q23)' 'acute Myeloid Leukemia with T(6;9)(p23;q34)'

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 327)
idRelated DiseaseScoreTop Affiliating Genes
1myelodysplastic syndrome32.4SETBP1, GATA2
2myelofibrosis31.6KIT, JAK2
3systemic mastocytosis31.6JAK2, KIT
4mastocytosis31.5CHIC2, KIT
5sarcoma31.3ETV6, JAK2, KIT, TERT, RUNX1, KRAS
6essential thrombocythemia31.3KIT, JAK2
7refractory anemia31.3FLT3, JAK2, RUNX1, KIT
8eosinophilia31.3ETV6, JAK2, CHIC2
9aplastic anemia31.2GATA2, TERT, FLT3
10chronic myelomonocytic leukemia31.2RUNX1, KIT, ETV6, JAK2, FLT3
11myeloid leukemia31.2NPM1, GATA2, KIT, ETV6, JAK2, FLT3
12polycythemia vera31.0KIT, FLT3, JAK2
13down syndrome31.0FLT3, JAK2, ETV6, GATA2, RUNX1
14acute myelomonocytic leukemia30.9RUNX1, ETV6
15myeloid sarcoma30.8FLT3, KIT
16breast cancer30.6NPM1, GATA2, KRAS, KIT, TERT, ETV6
17acute leukemia30.5NPM1, GATA2, KRAS, KIT, CEBPA, ETV6
18acute myeloid leukemia, adult30.5NPM1, KIT, FLT3, RUNX1
19leukemia, acute promyelocytic30.5FLT3, RUNX1, GATA2, NPM1
20leukemia30.4KRAS, GATA2, NPM1, ARHGEF12, KIT, CEBPA
21b-cell lymphomas30.4FLT3, JAK2, NPM1
22melanoma30.4KRAS, JAK2, FLT3, TERT, KIT
23precursor t-cell acute lymphoblastic leukemia30.0GATA2, PICALM, FLT3, NUP214, RUNX1, ETV6
24hematologic cancer30.0NPM1, KIT, JAK2, FLT3, PICALM, ETV6
25leukemia, acute lymphoblastic30.0JAK2, KIT, KRAS, GATA2, FLT3, ETV6
26cytogenetically normal acute myeloid leukemia11.1
27core binding factor acute myeloid leukemia11.0
28wilms tumor10.9
30hematopoietic stem cell transplantation10.8
32familial acute myeloid leukemia with mutated cebpa10.7
33acute myeloid leukemia with multilineage dysplasia10.7
37diabetes insipidus10.6
39refractory anemia with excess blasts10.6
40severe congenital neutropenia10.6
41invasive aspergillosis10.6
42multiple myeloma10.5
45minimally differentiated acute myeloblastic leukemia10.5
48'acute myeloid leukemia with t(9;11)(p22;q23)'10.5
49acute myeloblastic leukemia type 110.5
50acute myeloblastic leukemia type 210.5

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:

Diseases related to leukemia, acute myeloid

Symptoms for Leukemia, Acute Myeloid

About this section

Symptoms by clinical synopsis from OMIM:


Clinical features from OMIM:


HPO human phenotypes related to Leukemia, Acute Myeloid:

id Description Frequency HPO Source Accession
1 autosomal dominant inheritance HP:0000006
2 acute myeloid leukemia HP:0004808

Drugs & Therapeutics for Leukemia, Acute Myeloid

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Mylotarg13 38 GEMTUZUMAB OZOGAMICIN Wyeth Approved May 2000
FDA Label: Mylotarg
Malady that Drug Treats: Acute Myeloid Leukemia (AML)
Indications and Usage:13 Mylotarg is indicated for the treatment of patients with CD33 positive acute myeloid leukemia in; first relapse who are 60 years of age or older and who are not considered candidates for other; cytotoxic chemotherapy. The safety and efficacy of Mylotarg in patients with poor performance; status and organ dysfunction has not been established.; The effectiveness of Mylotarg is based on OR rates (see CLINICAL STUDIES section). There; are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related; symptoms or increased survival, compared to any other treatment.
DrugBank Targets:11 1. Myeloid cell surface antigen CD33; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. Complement C1s subcomponent; 9. High affinity immunoglobulin gamma Fc receptor I; 10. Low affinity immunoglobulin gamma Fc region receptor II-a; 11. Low affinity immunoglobulin gamma Fc region receptor II-b; 12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: CD33 antigen expressed by; hematopoietic cells
Action: binds to form complex that then causes a break in the DNA double strand
FDA: Mylotarg is directed against the CD33 antigen expressed by; hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33; antigen results in the formation of a complex that is internalized. Upon internalization, the; calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released; calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand; breaks and cell death.; Gemtuzumab ozogamicin is cytotoxic to the CD33 positive HL-60 human leukemia cell line.; Gemtuzumab ozogamicin produces significant inhibition of colony formation in cultures of adult; leukemic bone marrow cells. The cytotoxic effect on normal myeloid precursors leads to; substantial myelosuppression, but this is reversible because pluripotent hematopoietic stem cells; are spared. In preclinical animal studies, gemtuzumab ozogamicin demonstrates antitumor; effects in the HL-60 human promyelocytic leukemia xenograft tumor in athymic mice.

Drug clinical trials:

Search ClinicalTrials for Leukemia, Acute Myeloid

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS61/NDF-RT40:

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Genetic Tests for Leukemia, Acute Myeloid

About this section

Genetic tests related to Leukemia, Acute Myeloid:

id Genetic test Affiliating Genes
1 Aml - Acute Myeloid Leukemia22

Anatomical Context for Leukemia, Acute Myeloid

About this section

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

Myeloid, Bone, Bone marrow, Skin, Testes

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowCommon Myeloid Progenitor Cells Potential therapeutic candidate, affected by disease
2 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate

Animal Models for Leukemia, Acute Myeloid or affiliated genes

About this section

Publications for Leukemia, Acute Myeloid

About this section

Articles related to Leukemia, Acute Myeloid:

Concomitant chronic lymphocytic leukemia, acute myeloid leukemia, and thrombosis with protein C deficiency. Case report and review of the literature. (2646007)

Variations for Leukemia, Acute Myeloid

About this section

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

id Symbol AA change Variation ID SNP ID

Clinvar genetic disease variations for Leukemia, Acute Myeloid:

5 (show all 31)
id Gene Variation Type Significance SNP ID Assembly Location
1KRASKRAS, 3-BP INS, GLY11INSinsertionPathogenic
2KITNM_000222.2(KIT): c.2446G> T (p.Asp816Tyr)single nucleotide variantPathogenicrs121913506GRCh37Chr 4, 55599320: 55599320
3NPM1NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs)duplicationPathogenicGRCh38Chr 5, 171410540: 171410543
4NPM1NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs)insertionPathogenicGRCh38Chr 5, 171410543: 171410544
5NPM1NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs)insertionPathogenicGRCh38Chr 5, 171410543: 171410544
6NPM1NM_002520.6(NPM1): c.863_864insCCTG (p.Trp288Cysfs)insertionPathogenicGRCh38Chr 5, 171410543: 171410544
7JAK2NM_004972.3(JAK2): c.1849G> T (p.Val617Phe)single nucleotide variantPathogenic, risk factorrs77375493GRCh37Chr 9, 5073770: 5073770
8JAK2NM_004972.3(JAK2): c.1821G> C (p.Lys607Asn)single nucleotide variantPathogenicrs121912472GRCh37Chr 9, 5073742: 5073742
9FLT3NM_004119.2(FLT3): c.2520_2521insGGATCC (p.Ser840_Asn841insGlySer)insertionPathogenicrs398122514GRCh37Chr 13, 28592624: 28592625
10FLT3NM_004119.2(FLT3): c.2504A> T (p.Asp835Val)single nucleotide variantPathogenicrs121909646GRCh37Chr 13, 28592641: 28592641
11FLT3NM_004119.2(FLT3): c.2503G> C (p.Asp835His)single nucleotide variantPathogenicrs121913488GRCh37Chr 13, 28592642: 28592642
12FLT3NM_004119.2(FLT3): c.2503G> A (p.Asp835Asn)single nucleotide variantPathogenicrs121913488GRCh37Chr 13, 28592642: 28592642
13FLT3FLT3, ASP835GLUundetermined variantPathogenic
14FLT3NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr)single nucleotide variantPathogenicrs121913488GRCh37Chr 13, 28592642: 28592642
15FLT3NM_004119.2(FLT3): c.2503_2505delGAT (p.Asp835del)deletionPathogenicrs121913486GRCh37Chr 13, 28592640: 28592642
16CEBPANM_004364.4(CEBPA): c.115_121delCCCGCGC (p.Pro39Serfs)deletionPathogenicGRCh38Chr 19, 33302294: 33302300
17CEBPANM_004364.4(CEBPA): c.148G> T (p.Glu50Ter)single nucleotide variantPathogenicrs121912791GRCh37Chr 19, 33793173: 33793173
18CEBPANM_004364.4(CEBPA): c.251A> T (p.His84Leu)single nucleotide variantPathogenicrs28931590GRCh37Chr 19, 33793070: 33793070
19CEBPANM_004364.4(CEBPA)duplicationPathogenicGRCh38Chr 19, 33301424: 33301480
20CEBPANM_004364.4(CEBPA)duplicationPathogenicGRCh38Chr 19, 33301464: 33301490
21CEBPANM_004364.4(CEBPA): c.211_214dupGCCG (p.Ala72Glyfs)duplicationPathogenicGRCh38Chr 19, 33302201: 33302204
22CEBPANM_004364.4(CEBPA): c.68delC (p.Pro23Argfs)deletionPathogenicrs137852728GRCh38Chr 19, 33302347: 33302347
23CEBPANM_004364.4(CEBPA): c.141delC (p.Ala48Profs)deletionPathogenicrs137852730GRCh37Chr 19, 33793180: 33793180
24CEBPANM_004364.4(CEBPA): c.198_201dupCTAC (p.Ile68Leufs*41)duplicationPathogenicrs137852731GRCh37Chr 19, 33793120: 33793123
25CEBPANM_004364.4(CEBPA): c.217_218insC (p.Phe73Serfs)insertionPathogenicrs137852733GRCh37Chr 19, 33793103: 33793104
26CEBPANM_004364.4(CEBPA): c.318_319dupTG (p.Asp107Valfs*54)duplicationPathogenicrs137852732GRCh37Chr 19, 33793001: 33793002
27CEBPANM_004364.4(CEBPA): c.68dupC (p.His24Alafs)duplicationPathogenicrs137852729GRCh37Chr 19, 33793252: 33793253
28GATA2NM_001145661.1(GATA2): c.1061C> T (p.Thr354Met)single nucleotide variantPathogenic, risk factorrs387906631GRCh37Chr 3, 128200744: 128200744
29TGM6NM_198994.2(TGM6): c.1550T> G (p.Leu517Trp)single nucleotide variantPathogenicrs387907097GRCh37Chr 20, 2398091: 2398091
30ETV6NM_001987.4(ETV6): c.226G> T (p.Glu76Ter)single nucleotide variantPathogenicrs121434637GRCh37Chr 12, 11992136: 11992136
31ETV6NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly)insertionPathogenicGRCh37Chr 12, 12043928: 12043929

Expression for genes affiliated with Leukemia, Acute Myeloid

About this section
Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for genes affiliated with Leukemia, Acute Myeloid

About this section

Compounds for genes affiliated with Leukemia, Acute Myeloid

About this section

Compounds related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 37)
idCompoundScoreTop Affiliating Genes
1beta-tyrosine4410.4KIT, JAK2
2tandutinib4410.4FLT3, KIT
3pkc 4124410.3KIT, FLT3
4lestaurtinib44 6011.3FLT3, JAK2
5ag-12964410.3FLT3, KIT
6su54164410.2FLT3, KIT
7ponatinib50 1111.2KIT, FLT3
8methylcellulose4410.2GATA2, KIT, FLT3
9hydroxyurea44 50 1112.1GATA2, JAK2, KIT
10leptomycin b44 6011.1LPP, NUP214, NPM1
11sunitinib44 50 1112.1FLT3, KIT
12agarose4410.0FLT3, KIT, NPM1
13gp 1304410.0JAK2, KIT, FLT3
14paclitaxel44 50 1111.9KRAS, KIT, TERT, NPM1
15paraffin449.8KRAS, TERT, KIT, NPM1
16valine449.8KIT, JAK2, KRAS
17phosphoinositide449.8FLT3, KRAS, KIT, JAK2
18regorafenib50 1110.8KIT, KRAS
19l-glutamine28 24 1111.7GMPS, TGM6
205-aza-2deoxycytidine449.7JAK2, FLT3, TERT
21aspartate449.7GMPS, JAK2, FLT3, NPM1, KIT
22leucine449.7GATA2, NPM1, PICALM, JAK2, CEBPA, KIT
23cycloheximide449.7KIT, GATA2, NPM1, JAK2
24arsenite44 2410.6JAK2, FLT3, RUNX1, TERT
25thymidine44 2410.6KIT, TERT, FLT3, JAK2
26butyrate449.5RUNX1, TERT, JAK2, GATA2, KRAS
27phosphatidylinositol449.5TERT, FLT3, KRAS, KIT, JAK2
28doxorubicin44 50 1111.5RUNX1, NPM1, KIT, FLT3, TERT
29atp44 2810.4KIT, JAK2, GMPS, NPM1, FLT3
30rapamycin449.4NPM1, KIT, JAK2, FLT3, TERT, KRAS
31imatinib44 50 1111.3RUNX1, KRAS, KIT, ETV6, JAK2, FLT3
32estrogen449.3NPM1, CEBPA, GATA2, KRAS, KIT, JAK2
33threonine449.2NPM1, KIT, RUNX1, TERT, FLT3, JAK2
34vegf449.0KIT, ETV6, JAK2, FLT3, TERT, RUNX1
35oligonucleotide448.9FLT3, RUNX1, ARHGEF12, GATA2, KRAS, KIT
36tyrosine448.6ETV6, NPM1, FLT3, JAK2, KIT, KRAS
37retinoic acid44 249.4JAK2, CEBPA, FLT3, TERT, RUNX1, KIT

GO Terms for genes affiliated with Leukemia, Acute Myeloid

About this section

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleusGO:00056347.9NPM1, PICALM, NUP214, SETBP1, JAK2, CEBPA

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.2KIT, JAK2
2definitive hemopoiesisGO:006021610.1GATA2, RUNX1
3myeloid cell differentiationGO:003009910.0RUNX1, CEBPA
4positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.0KIT, JAK2
5positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.0KIT, JAK2, FLT3
6embryonic placenta developmentGO:000189210.0CEBPA, GATA2
7embryonic hemopoiesisGO:003516210.0RUNX1, KIT
8peptidyl-tyrosine phosphorylationGO:001810810.0FLT3, JAK2, KIT
9myeloid progenitor cell differentiationGO:00023189.9KIT, FLT3, RUNX1
10negative regulation of cell proliferationGO:00082859.7FLT3, JAK2, CEBPA, NPM1
11protein autophosphorylationGO:00467779.7KIT, JAK2, FLT3
12hemopoiesisGO:00300979.7RUNX1, PICALM, FLT3, KIT
13positive regulation of phosphatidylinositol 3-kinase activityGO:00435529.7KIT, FLT3
14positive regulation of cell proliferationGO:00082849.6KRAS, KIT, JAK2, FLT3
15cytokine-mediated signaling pathwayGO:00192219.3KRAS, NUP214, FLT3, JAK2, CEBPA, KIT

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transmembrane receptor protein tyrosine kinase activityGO:000471410.0KIT, FLT3
2phosphatidylinositol 3-kinase bindingGO:00435489.6JAK2, FLT3
3protein homodimerization activityGO:00428038.8RUNX1, TERT, FLT3, CEBPA, KIT, NPM1
4protein bindingGO:00055156.7ARHGEF12, RUNX1, TERT, PICALM, NUP214, FLT3

Sources for Leukemia, Acute Myeloid

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet